精准治疗时代下广泛期小细胞肺癌联合治疗研究进展
Advances in Systemic Therapy for Extensive-stage Small Cell Lung Cancer in the Era of Precision Treatment
摘要
Abstract
Extensive-stage small cell lung cancer(ES-SCLC)is characterized by rapid progression,a high risk of recurrence,and poor prognosis,and remains a major therapeutic challenge in lung cancer.In recent years,immune checkpoint inhibitors combined with Platinum-Etoposide chemotherapy have become the standard first-line treatment for ES-SCLC,driving a shift from conventional chemotherapy toward multimodal combination strategies and precision-guided patient stratification,while creating both new opportunities and challenges for further therapeutic improvement.Following the clinical treatment pathway,this review summarizes advances in multidisciplinary combination treatment for ES-SCLC,including chemotherapy,immunotherapy,targeted therapy,radiotherapy,and traditional Chinese medi-cine,with emphasis on standard regimens,maintenance therapy,clinical limitations,and emerging research directions.This review aimed to provide a reference for individualized treatment and comprehensive disease management of ES-SCLC in the era of precision medicine.关键词
肺肿瘤/小细胞肺癌/免疫疗法/免疫检查点抑制剂/抗血管生成/靶向治疗/放疗/中医药/精准医学Key words
Lung neoplasms/Small cell lung cancer/Immunotherapy/Immune checkpoint inhibitors/Angiogen-esis inhibitors/Targeted therapy/Radiotherapy/Traditional Chinese medicine/Precision medicine引用本文复制引用
陈涵芮,徐俪雯,程奕暄,周蕾..精准治疗时代下广泛期小细胞肺癌联合治疗研究进展[J].中国肺癌杂志,2026,29(7):500-508,9.基金项目
This paper was supported by the grants from the National Project for Advancing Key Specialized Clinics in Traditional Chinese Medicine(Traditional Chinese Medicine Oncology)(No.XH40202-202509040,to Hegen LI),National Project for High-level Key Disciplines in Traditional Chinese Medicine(Oncology),Ministry of Traditional Chinese Medicine(No.zyyzdxk-2023063,to Hegen LI),National Medical Center Clinical Research Project(No.GFB2401-1-1,to Lei ZHOU),Long-hua Hospital of Shanghai University of Traditional Chinese Medicine Shanghai New Three-Year Action Plan Research Project(No.GFB2502,to Lei ZHOU)and Health Commission of Pudong New Area,Shanghai Municipality,Joint Research Project(No.PW2024D-13,to Lei ZHOU). 本文受国家中医优势专科建设项目(中医肿瘤)(No.XH40202-202509040)、国家中医药管理局高水平中医药重点学科建设项目(中医肿瘤病学)(No.zyyzdxk-2023063)、上海中医药大学龙华医院国家医学中心临床研究项目(No.GFB2401-1-1)、上海市新三年行动计划研究项目(No.GFB2502)和上海市浦东新区卫生健康委员会联合攻关项目(No.PW2024D-13)资助 （Traditional Chinese Medicine Oncology）
